Are you tempted by the AstraZeneca share price? Here’s what you need to know

AstraZeneca plc (LON: AZN) might look like an attractive cash cow, but what’s the downside of the stock?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

A very wise man (a certain Mr Buffett) once said that your first aim in investing should be to avoid losing money — which is the exact opposite of what many people have in mind when they’re starting out.

What it means is to analyse the safety of your potential investments, minimise any possible downside, and only buy shares when they’re offering you good value. If you do that and focus on avoiding losses, you might be surprised by how the profits can take care of themselves.

In that light, I’m re-examining some of my favourite FTSE 100 companies, looking for reasons why not to buy them — those things that new investors really need to know. Today it’s pharmaceuticals giant AstraZeneca (LSE: AZN).

You might not see much immediate danger of losing money on a stock that has gained a mouthwatering 78% over the past five years, while rewarding its shareholders with dependable dividends along the way. But there’s a lot more to the AstraZeneca picture than that.

Tough time

Declining profits is the big problem, and we’ve seen years of falling earnings per share now, and those dividends have been taking up increasing proportions of the company’s earnings. In fact, for the current year we can see a forecast yield of about 3.5%, but that would not be very well covered by earnings — and that’s an important thing for a company that needs to plough back a big chunk of earnings into research and development every year.

The problem has been long in the making, caused by the ending of some lucrative key drug patents and hot competition from generic alternatives. The current chief executive, Pascal Soriot, was brought in to try to turn the ride in 2012, and his actions were swift.

After dumping some non-core business and refocusing on long-term drugs development, the company today looks in significantly better shape. But when it comes to a return to growing earnings, we’ve seen a few false starts — forecasts suggesting 2015, maybe 2016, or perhaps 2017…

But the truth is, three years of flat earnings is all that has been achieved so far, and there’s an EPS drop of more than 20% currently predicted for this year. A 12% rebound indicated for 2019 would recover some of that, but it’s hardly back to overall growth.

Any bears?

I regularly read the writings of my fellow Motley Fool writers, and I’ve been looking for bearish views on AstraZeneca from them — but it’s hard to find any negative thoughts at all. The closest is Peter Stephens, who has examined the contrast between the falling earnings of the past five years and the share price rise. But he still likes the outlook.

That outlook has been improving, with hardly a week going by without news of progress on the company’s many drug developments. The latest was Thursday, after the firm received European Commission approval for a new formulation of one of its type-2 diabetes treatments.

Other successes in the same month include Japanese approval for a cancer treatment, and an orphan drug designation for another cancer treatment in the US (which essentially assists in its evaluation and development).

On forward P/E multiples of around 20, AstraZeneca is not the bargain it once was, but I agree with Peter that it’s “cheap given its future prospects.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »